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Abstrac t 
PholOdynamic therapy (PDT) is a cancer treatment modality thaI recently has been applied as adjuvant therapy for 
brain tumors. PDT consists of intravenously injecting a photosensitizer. which preferentially accumulates in tumor 
cells. into a patien! and then activating the photosensitizer with a light source. Th is results in free radical generation 
followed by cell death. The development of more effective light sources for PDT of brain tumors has been 
faci litated by applications of space light-emining d iode array technology; thus pennitting deeper tumor penetration 
of light and use of bener photosensitizers. Current ly, the most commonly used photosensitizer for brain tumor PDT 
is Photofrin®. Photofrin® is a heterogeneous mixture of compounds derived from hematoporphyrin . Photofrin® is 
activated with a 630 nm laser light and does destroy tumor cells in animal models and humans. However. treatment 
failure does occur using this method. Most investigators attribute this failure to the limited penetration of brain 
tissue by a 630 nm laser light and to the fact that Photofrin® has only a minor absorption peak at 630 nm , meaning 
that only a small fraction of the chemical is activated. Benzoporphyrin Derivati ve Monoac id Ring A (BPD) is a 
new. second generation photosensitizer that can potentially improve PDT for brain tumors. BPD has a n1aj or 
absorption peak at 690 nm. which gives it two distinct advantages over PhOlOfrin®. First, longer wavelengths of 
light penetrate brain tissue more easily so that larger tumors cou ld be trealed, and second, the major absorption peak 
means that a larger fraction of the drug is activated upon exposure to light. In the first part of this project we have 
studied the tumoricidal effects of BPD in vitro using 2A9 canine glioma and U373 human glioblastoma cell 
cultures. Usi ng light emitting diodes (LED) with a peak emission of 688 nm as a light source. cell kill of up to 86 
percent was measured in these cell lines by tumor DNA synthesis reduction . The effectiveness of BPD against 
tumor cells in vi/ro thus established, we have taken Ihe first step toward detemlining its effectiveness in vivo. The 
second part of this project consisted of experiments perfonned to determine the maximum tolerated dose (MTD) of 
both BPD and LED light. At a light dose of 100 J/cm2, skin damage and neurolOxicity were seen at a BPD dose of 
1.0 mg/kg, but not at a dose of 0 .75 mg/kg. When BPD remained constant at 0.75 mglkg. skin damage was seen at 
lighl dosages of 125 J/cml, 150 J/cm 2 and 175 J/cm2• One dog also died at a light dose of 175 J/cm 2• Further studies 
will be needed to detennine the effectiveness of BPD against tumor cells in vivo. 
INTRODUCTION 
Photodynamic therapy (PDT) is a relatively new adjuvant treatment for brain tumors in research and in clinical 
practice (J i 1992, Kaye 1987, Kostron 1987, Laws 1981 , Lindsay 1991. MuHer 1990. Powers 1991 . Sc hmidt 1994. 
and Whelan 1993). The cytotoxic photodynamic effect is based upon Ihe interaction ofa localized photosensitizer, 
light and oxygen (Henderson 1992). Photofrin® is currently the most commonly used photosensitizer for PDT of 
brain tu mors. Photofrin® is a heterogeneous mixture of hematoporphyrin which accumulates preferentially in brain 
tumors (Hill 1990, Kaye 1988, Whelan 1993. and Whelan I 994). The absorption spectrum of photofrin® is 
relatively broad with two significant absorption peaks: a major absorption peak at 390 nm and a minor absorption 
peak at 630 nm (Kaye \988). Traditionally, red laser light with a wavelength of 630 nm has been used to activate 
photofrin®, the decreased absorbance of this wavelength by photofrin® being compensated for by the increased 
penetrance of brain tissue demonstrated by longer wavelengthS of light. Red laser light is frequentl y produced by 
using an Argon ion or KTPfYAG laser beam that is convened by a dye module to 630 nm . This conversion is 
inherently costly and inefficient, but allows for light to be delivered by fibe roptics. For non-fiberoptic delivery of 
light, other light sources could be a potentially usefu l altemative . 
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Light-emitting diodes (LED) are one such light source that may prove to be an effective alternative to lasers for 
PDT. LED's have been frequently used to emit low power, broad spectrum light of 25-30 nm bandwidth for 
photosynthesis research in plants (Barta 1992, Bula 1991, and Tennessen 1994). LED lamps traditionally consist of' 
an array of semiconducting LED chips. In recent years, improvements in semiconductor technology have 
substantially increased the light output of LED chips. A novel type of LED chip is based on the semiconductor 
Aluminum Gallium Arsenide (AIGaAs). These LED chips can be manufactured to emit light with a peak 
wavelength between 630 nm and 940 nm (Bula 1991, and Tennessen 1994). This range of wavelengths overlaps 
with the absorption spectrum of photo sensitizers used for PDT of brain tumors. 
The purposes of this study were to test the cytotoxicity of the LED/BPD combination against 2A9-canine glioma 
and U373 human gl ioblastoma cells in vilro, and to detennine the maximum tolerated dose (MTD) of both LEO. 
derived light and BPD in dogs. 
METHODS 
Photodynamic effect in vitro was tested using an LED array to direct light into culture dishes containing tither 
BPD-sensitized cells. or control cells. DNA synthesis was then measured to assess cell damage. In vivo 
photodynamic therapy studies were performed using an LED probe inside a fluid filled balloon. The balloon was 
placed into the posterior fossa of adult dogs, some of which had received BPD and some of which were non-
photosensitized controls. Varying doses of BPD and LED light were administered to detennine the maximum 
tolerated doses of both. 
Photodynamic St ud ies of Glioma In Vilro 
Assays of photodynamic effect were conducted using a flat LED array to direct light into culture dishes containing 
brain tumor ce ll s in both the presence and absence of BPD; the ability of the cells to perfonn DNA synthesis was 
then measured. Red light for PDT in vilra was produced by a Q-Beam photosynthesis lamp (Quantum Devices. 
Inc :. Barneveld. WI. USA). The emitting surface of this lamp measured 6 x 10 cm and contained 198 LED chips on 
top of a ceramic sink and a cooling fan . The intensity of the emined red light was modulated via a ten tum 
potentiometer which controlled the current to the LED chips. The glioma cells for the in vitro experiments wert 
exposed to 100 J/cm2• The temperature at the emitting surface did not exceed 37° C at any time during the 
experiments. 
Canine glioma clones were grown in a monolayer tissue culture in PIOO tissue culture dishes at 37° C in a 
humidified, five to ten percent CO! atmosphere, as previously described (Schm idt. 1996). Cultures were harvested 
by gently dislodging the cells from their substratum with a Pasteur pipette for in vitro assay. Canine glioma cells 
were then plated in the 1.6 coo well of a 24 plate. Following twenty four hours of attachment. BPD was added in 
concentrations of 5. 10,20 and 60 nglml in five percent dextrose solution. This concentration did not produce any 
dark toxicity in our cell line. All experiments were done in sixlettes. Light-only control cells received an equal 
volume of five percent dextrose solution without BPD. After 30 minutes of incubation in the dark. the cells were 
exposed to light from an LED lamp as described above. 
Approximately two hours after completion of light exposure, Ireatment cell viability was assessed by measuring 
uptake of l H-Thymidine in DNA. Cells were exposed to I !lCi of lH-Thym idine. After four hours of jH· 
Thymidine exposure, the medium was removed. The monolayer of glioma cells was washed with cold phosphate 
buffered saline solution. Then the acid soluble material was extracted with a ten percent trichloroacetic acid (TCA) 
solution for fifteen minutes. The TCA solution was subsequently removed and the monolayer transferred into a 
scint illation vial and thoroughly mixed with scint illation fluid . Radioactivity was counted in a Beckman LS 
6000TA liquid scintillation spectrometer. 
Photodynamic Th erapy St udies In Vivo 
In order to deliver LED light in vivo and compare it to the conventional laser balloon adapter. an LED probe waS 
constructed (Hgure I). The LED probe consists of a 10 coo hollow steel tube that has at its tip 144 LED ch ips 
730 
arranged in a cylinder. The core of the tube contains three channels. One channel contains insu lated wires which 
provide electric ity for the LED tip. A second channel contains sterile water which acts as a cooling fluid when 
circulated around the tip. The third channel provides access for the 0. 1 percent intralipid fluid used to inflate the 
balloon at the tip of the probe . The pump for the cooling fluid and the power supply are in a portable base unit. 
power output of the LED tip is adjusted via a potentiometer on the base unit which contro ls current flow. The 
temperature of the tip was continuous ly monitored and was not allowed to exceed 35 0 C at any time during the 
experiment. The balloon of the LED probe was in flat ed with a 0.1 percent intralipid solution. Balloon diameter 
ranged from 2 cm to 5 cm. The tip of the LED probe was placed in the center of the balloon. In this configuration, 
the balloon is known to scatter light uniformly, with light irradiation varying by no more than twenty percent of the 
average when measured at any point on the balloon's surface (Schmidt, et ai, 1996). The total power output was 1.0 
watt at the tip and was kept constant for all measurements. 
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FIGURE I. The LED balloon applicator in a schematic overview. 
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Adull mongre l dogs each weighing approximately 20 kg were used for in vivo PDT. All animals were intubated 
and placed under general anesthesia using halothane/nitrous oxide. The head of the canine was securely fixed to a 
head frame and maximally fl exed. Using a posterior approach, the suboccipital bone and C I vertebra were exposed. 
A wide craniectomy was performed using a power drill. A Y -shaped dural incision exposed the cerebellum, lower 
brainstem and upper cervical spinal cord. The balloon applicator with a diameter of 2 cm was placed into the 
posterior fossa on the brainstem. Self-retaining retractors were used to secure the balloon applicator to prevent 
excessive pressure from being place onto the brainstem. 
To determine the MTD of BPD, seven dogs were used. These dogs all received 100 J /cm ~ of LED light. with the 
dosage of BPD being the control variable. One dog received no BPO, three dogs received 0.75 mglkg of BPD and 
three dogs received 1.0 mglkg of BPO. The MTO was defined as the dose given to the group of canines that 
preceded the group with a 50 percent clinical toxicity rate. 
To determine the MTD of LED light, eleven dogs were used. These dogs all received the MTD of BPD 
determined above, and varying amounts of LED light . BPD was administered three hours prior to li&ht application ; 
there was no BPD only group. Three dogs received 125 J/cm2 of LED light, three received 150 J/cm', four received 
175 J /cm~ and one received 200 J/cm2. These dogs were then split into two groups. Those receiving less than or 
equal to 150 J/cm! of light and those receiving more than 150 J/cm1 of light. 
Canines from both portions of the in vivo study were monitored for skin toxicity and neurotoxicity. and were given 
an MRI to assess damage. 
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RESULTS 
The LED lightlBPD combination showed photodynamic effects in vitro which resulted in reduced DNA synthe 
in experimental cells versus non-photosensitized cOnlrol cells. In vivo results indicate that there is a defin 
sis 
ite 
maximum tolerated dose of both LED Jight and BPD over which skin and neurotoxicity results . 
Photod ynamic Studies o( G lioma It, Vireo 
00 There was no significant difference between glioma cells that received LED light only and cells that had 
treatment . LED light exposure of BPD sensitized cells resulted in a significant reduction in the amounl of ON 
synthesis perfonned by 2A9 canine glioma and U373 human glioma cells. The effects of LE D light and BPD 
A 
'" illustrated in Figure 2 and Table I. 
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FIGURE 2. Photodynamic Effect of BPD In Vitro. 
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TABLE I. DNA SYnlhesis (Percent ofConlro 
at Varying BPD Concentrations. 
BPO Conc. DNA (% of control) 
(og/ml) SYnlhesis U373 Hum 
2A9 Canine Glioma 
Glioma 
o 100 ± 3.77 100 ± 9.45 
5 79.59 ± 4.26 19.05 ± 1.28 
10 39.02 ± 1.44 16.91 ± 1.91 
20 32.28 ± 1.52 16.18 ± l.ll 




When 100 J/cm2 of LED light was used in the absence of BPO, no skin toxicity or neurotoxicity resulted. Wh 
100 J/cm2 of LED light and .75 mglkg of BPO were used together, again, no toxicity resulted. In COnlrast, when 
J/cm2 and 1.0 mg/kg of BPD were used, two dogs displayed skin toxicity, and three dogs displayed transi 
neurotoxicity. None of the dogs that received 100 J/cm2 of LED light in combination with any amount of BPD d 
or showed signs of damage on MRL Table 2 summarizes these results. 
TABLE 2 Results From Dogs Receiving 100 Jlcm2 0fLED Light 
Light Dose BPD Dose Number of Cases of Cases of Deaths MRI-visible 
Dogs Skin Neuro- damage 
Toxicity toxicity 
100 J/cm- 0.0 mglkg I 0 0 0 none 
100 J/cm- .75 mglkg 3 0 0 0 none 
100 J/cm- 1.0 mg/kg 3 2 3 0 none 
When 0.75 mg/kg of BPD was used in combination with doses of LED light less than or equal to 150 Jfc 
tox icity of any kind was uncommon. In these nine dogs, we saw only two· cases of skin loxicity, and 
neurotoxicity, death or MRI-visible damage. In the five dogs receiving 0.75 mglkg of BPD and more than 








TABLE 3. Results From Dogs Receiving 0.75 mglkg of BPD. 
Light D BPD Dose Number of Cases of Cases of Deaths MR[·visib1e 
damage Dogs Skin Neuro-
Toxicity toxicity 
~ 1 50 J/c m .75 mglkg 9 2 o o none 




development of new light sources and light delivery devices is of critical impor1ance for improving 
namic therapy. In this study an LED probe with an inflatable tip was used instead of the traditional laser 
rce. The concept of using a fluid filled balloon to photo-illuminate a tumor cavity after maximal resection 
inally put forward by Muller and Wilson (Muller 1985, Muller 1986 . Muller 1987. Muller 1990. and 
986). They developed a laser balloon adapter in which the red laser light, produced at the power module. 
red via a fiberoptic to the center of a fluid filled balloon. The fluid inside the balloon serves as a light 
g medium. In addition. the inflated balloon prevents the collapse of the resection cavity which could 
Iy prevent light from reaching sensitized tumor cells. The LED probe is similar to the laser probe in that a 
ed balloon is used to scaner light. However, the LED probe does not require a fiberoptic for light delivery. 
ght is produced at the tip of the probe in the center of the balloon . This arrangement eliminates the 
mately 50 percent loss of power seen between the laser light source and the target tissue when using the laser 
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er advantage of using LED probes over lasers for PDT is the increased range of wavelengths that can be 
d by them . As mentioned previously, red laser light is frequently produced using an Argon ion or 
G laser beam, and then conver1ed to the 630 nm wavelength needed to activate photofrin® by a costly 
LED arrays can be manufactured to emit a wide range of wavelengths, eliminating the need for this 
KTPIYA 
process: 
process. One can simply order the LED needed for activation of the chosen photosensitizer. The availability of 
avelength light sources allows for the use of newer, second generation photosensitizers such as BPD. As 
ly mentioned. BPD has several characteristics which make it more anractive for PDT of brain tumors than 
n® . BPD has a major absorption peak at both 415 and 690 nm , which gives it twO distinct advantages. 
nger wavelengths of light penetrate brain tissue more easily . This means that the 690 nm wavelength light 
tivate photosensitizer in the center of tumors that could not be reached by a 630 nm light . Second, the 
on peak at 690 nm is a major one which means that a larger fraction of the BPD is activated upon exposure 
than that which would be activated by exposing photofrin® to light. BPD also causes the fonnation of 
five times the amount of singlet oxygen molecules as the equivalent amount of photofrin®. can be 
ered much closer to the time of light exposure and causes shoner periods of skin toxicity in patients 
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CONe LUSIONS 
TABLE 4. Characteristics of Photofrin and BPD 
Photofrin® BPD 
365 nm (major) and 630 nm 
(minor) 
0.16 
18 to 72 hours 
4 weeks 
415 nm (major) and 690 nm 
(major) 
0.78 
15 min to 4 hours 
24 hours 
In vi Iro photodynamic therapy using BPD and LED light is effective against canine and human glioma cells. 
tering a concentration of 10 ng/ml of BPD 30 minutes prior to light application reduces DNA synthesis by 




Photodynamic Studies of Glioma In Vjtro 
Based on our results, we conclude that photodynamic therapy, using the LED light source and BPO 
photosensitizer combination, is effective against 2A9 canine glioma and U373 human glioma cells in vitro. We 
also conclude that a BPO concentration of 10 nglml or higher will result in a greater than 50 percent reduction in 
DNA synthesis, and that 30 minutes is adequate time to allow for uptake of the BPO in vitro. In addition, human 
glioma cells were more sensitive than canine glioma cells in vitro. 
Photodynamic Therapy Studies In Vivo 
The results of this portion of the study indicate that the MTD ofBPD is 0.75 mg/kg and the MTD of LED light is 
between 100 and 150 J/cm 2 in dogs. Minor local skin damage is encountered at these doses. 
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